Merck & CompanyvsVaxcyte

MRK and PCVX stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$143.37

Value $354B

-2.23%
MRK's page

PCVX

Vaxcyte, Inc.

$59.40

Value $9.4B

-2.78%
PCVX's page

Merck & Company (MRK) has a market value of $354B and Vaxcyte (PCVX) $9.4B. Over the last year, with dividends, MRK moved +60.0% and PCVX +26.5%. Dividend yield: MRK 2.37%, PCVX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$354B

    PCVX$9.4B

    MRK is 38 times PCVX

  • Revenue, 12 months

    MRK$67.4B

    PCVX–

  • Net income, 12 months

    MRK$2.5B

    PCVX-$1.1B

  • Operating margin

    MRK–

    PCVX–

  • ROIC

    MRK3.9%

    PCVX-27.2%

    31.1 points apart

  • P/E

    MRK144.5

    PCVX–

  • Dividend yield

    MRK2.4%

    PCVX0.0%

    2.4 points apart

  • 5-year return

    MRK+101.1%

    PCVX+136.2%

    35.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+101.1%

PCVX+136.2%

20040020222023202420252026
Returns by period
PeriodMRKWith dividendsPCVXWith dividends
1 year since November 14, 2025+60.0%Price +55.5%+26.5%Price +26.5%
3 years since November 16, 2023+55.2%+15.8% a yearPrice +41.6%+23.0%+7.1% a yearPrice +23.0%
5 years since November 15, 2021+101.1%+15.0% a yearPrice +72.6%+136.2%+18.8% a yearPrice +136.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyPCVXVaxcyte

Valuation

MRKPCVX
Valuation
Price$143.37$59.40
Market value$354B$9.4B
Enterprise value (EV)$399B$8.2B
P/E144.5–
P/E, 5-year median14.8–
P/B7.93.8
EV/EBIT83.7–
Free cash flow yield4.2%–

Results and growth

MRKPCVX
Results and growth
Revenue, 12 months$67.4B–
Net income, 12 months$2.5B-$1.1B
Free cash flow, 12 months$14.7B-$974M
Earnings per share, 12 months$0.98-$8.06
Revenue growth, year on year1.3%–
Revenue growth a year, past+9.4%over 5 years–
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKPCVX
Margins and returns on capital
Gross margin71.8%–
Operating margin––
Net margin3.6%–
ROIC3.9%-27.2%
ROE5.2%-41.6%

Balance sheet

MRKPCVX
Balance sheet
Cash$9.7B$1.3B
Total debt$53.8B$222M
Net debt / EBITDA5.7–
Interest cover2.4×–

Dividends and buybacks

MRKPCVX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%–
Shareholder yield3.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or PCVX

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Vaxcyte?

By market value, Merck & Company ($354B) is about 37.7 times Vaxcyte ($9.4B), at today's prices.

How did MRK and PCVX stock do over the last 5 years?

Since November 15, 2021, MRK's price moved +72.6% and PCVX's +136.2%. With dividends: MRK +101.1% (+15.0% a year), PCVX +136.2% (+18.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or PCVX?

The dividend yield at today's price is 2.37% for Merck & Company and none for Vaxcyte. Over the last twelve months they paid $3.40 and – per share.

Which is the better investment, Merck & Company or Vaxcyte?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.